An Empowering Choice for an Allergy-Free Life
Milikast-FX Summary Table
| Parameter | Details |
|---|---|
| Brand name | Milikast-FX |
| Composition | Fexofenadine Hydrochloride 120 mg + Montelukast Sodium 10 mg |
| Dosage form | Film-coated tablet |
| Pharmacological class | Second-generation antihistamine + Leukotriene receptor antagonist |
| Mechanism of action | Fexofenadine: Selective peripheral H₁ receptor antagonist that blocks histamine-mediated allergy symptoms without sedation. Montelukast: CysLT₁ receptor antagonist that inhibits leukotriene-mediated inflammation and bronchoconstriction. |
| Therapeutic rationale | Dual-pathway therapy targets both histamine and leukotriene pathways, offering faster, broader, and more comprehensive relief than monotherapy. |
| Indications | • Seasonal & perennial allergic rhinitis • Hay fever • Nasal & ocular allergic symptoms • Mild allergic asthma |
| Recommended dose | One tablet once daily (adults / ≥12 yrs) or as prescribed by physician |
| Onset / duration | Rapid onset of symptom relief; 24-hour duration of action |
| Contraindications | Hypersensitivity to fexofenadine, montelukast, or excipients; not for acute asthma attacks |
| Common adverse effects | Headache, mild dizziness, nausea, dry mouth |
| Rare adverse effects | Neuropsychiatric events, hypersensitivity reactions |
| Drug interactions | Separate from antacids by ~2 hours; review concurrent CNS depressants or CYP3A4-metabolized drugs |
| Special precautions | Not a rescue medication; monitor patients for rare neuropsychiatric effects; caution in renal/hepatic impairment |
| Storage | Store below 25 °C, dry and protected from light; keep out of children’s reach |
| Key advantages | • Comprehensive relief of nasal and ocular allergy symptoms • Non-sedating, suitable for daily use • Dual-pathway action (histamine + leukotriene) • Once-daily convenience |
| Clinical evidence grade | Supported by randomized trials, observational studies, and post-marketing evidence (Level I–II evidence) |
Composition: Fexofenadine Hydrochloride 120 mg + Montelukast Sodium 10 mg
Dosage Form: Film-coated tablet
Therapeutic Class: Antihistamine + Leukotriene receptor antagonist
Indications: Allergic rhinitis • Seasonal allergies • Nasal and respiratory allergies • Mild allergic asthma
Product Summary
Milikast-FX is a dual-action anti-allergic formulation combining Fexofenadine, a second-generation non-sedating antihistamine, and Montelukast, a leukotriene receptor antagonist that targets inflammatory mediators. This synergistic pairing provides broad relief from allergic rhinitis, hay fever, and respiratory allergies while improving patient comfort and quality of life (Sanofi India Ltd., 2024; OJS UK Science Publication, 2023).
A once-daily regimen ensures convenience and adherence, offering sustained relief from nasal symptoms (sneezing, congestion, rhinorrhea) and ocular symptoms (itching, watering, redness) with minimal sedation (PharmEasy, 2024).
Composition
| Ingredient | Strength | Role |
|---|---|---|
| Fexofenadine Hydrochloride | 120 mg | Non-sedating H₁ antihistamine that blocks histamine-mediated allergic responses |
| Montelukast Sodium | 10 mg | Leukotriene receptor antagonist that reduces airway inflammation and bronchoconstriction |
Mechanism of Action
Fexofenadine
Fexofenadine selectively blocks peripheral H₁ histamine receptors, preventing histamine from inducing allergic symptoms such as sneezing, itching, and rhinorrhea. Because it does not cross the blood–brain barrier effectively, it causes little or no sedation and minimal anticholinergic effects (Wikipedia, 2025a; Sanofi India Ltd., 2024).
Montelukast
Montelukast acts by antagonizing cysteinyl leukotriene (CysLT₁) receptors, thereby preventing leukotriene-induced inflammation, bronchoconstriction, and mucus secretion in the airways (Wikipedia, 2025b). This mechanism complements histamine blockade, offering additional control in allergic airway diseases (Continental Hospitals, 2023).
Dual-pathway advantage: Histamine inhibition (Fexofenadine) + Leukotriene antagonism (Montelukast) = broader and faster symptom control (OJS UK Science Publication, 2023; Search BVS, 2022).
Clinical Benefits
- Comprehensive relief from nasal and ocular allergic rhinitis symptoms
- Reduction of seasonal and perennial allergy manifestations
- Improves airway comfort in allergic asthma
- Fewer relapses and better day-to-day function
- Non-sedating, suitable for long-term use
- Once-daily compliance improves treatment success (PharmEasy, 2024; TrueMeds, 2024)
Dosage & Administration
- Adults and adolescents (≥ 12 years): One tablet once daily, with or without food, preferably in the evening or as directed by a physician.
- Children (< 12 years): Use only under medical supervision.
- Missed dose: Skip and continue regular schedule; do not double the next dose.
- Administration: Swallow tablet whole with water (Steris Online, 2023).
Indications
- Allergic rhinitis (seasonal or perennial)
- Hay fever / pollinosis
- Nasal and ocular allergic symptoms
- Respiratory allergies with mild asthma components (Sanofi India Ltd., 2024)
Contraindications
- Hypersensitivity to fexofenadine, montelukast, or formulation excipients
- Not indicated for acute asthma attacks or status asthmaticus (Sanofi India Ltd., 2024)
Warnings & Precautions
- Not a rescue medication: Continue prescribed inhaled bronchodilators for acute asthma (Sanofi India Ltd., 2024).
- Neuropsychiatric effects: Rare mood or behavior changes may occur with montelukast; monitor closely (Wikipedia, 2025b).
- Hepatic / renal impairment: Use cautiously; dosage adjustments may be needed (TrueMeds, 2024).
- Alcohol / CNS depressants: Avoid concurrent use to minimize drowsiness (PharmEasy, 2024).
- Drug interactions: Separate dosing from aluminium or magnesium-based antacids by ~2 hours (Drugs.com, n.d.).
Adverse Effects
Most adverse events are mild and self-limiting:
Common: Headache, dizziness, nausea, dry mouth, mild drowsiness (TrueMeds, 2024).
Uncommon: Rash, abdominal discomfort, sleep disturbance (PharmEasy, 2024).
Rare: Hypersensitivity reactions, mood changes (Wikipedia, 2025b).
Report persistent or severe side effects to a healthcare professional.
Storage
- Store below 25 °C in a dry, dark place.
- Keep out of reach of children.
- Do not use after expiry date.
Why Choose Milikast-FX?
- Dual-action therapy targeting both histamine and leukotriene pathways
- Clinically proven improvement in allergic rhinitis symptoms in Indian studies (Search BVS, 2022)
- Minimal sedation and excellent safety profile (Sanofi India Ltd., 2024)
- Convenient once-daily dose ensures adherence
- Enhances comfort, breathing, and quality of life (Continental Hospitals, 2023)
Disclaimer
This material is intended for informational and educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Use Milikast-FX only under the supervision of a licensed healthcare provide
References
Continental Hospitals. (2023, June 14). Montelukast and Fexofenadine combination for allergy relief. Retrieved October 21, 2025, from https://continentalhospitals.com/blog/montelukast-and-fexofenadine-combo-for-allergy-relief/
Drugs.com. (n.d.). Allegra and montelukast drug interactions. Retrieved October 21, 2025, from https://www.drugs.com/drug-interactions/allegra-with-montelukast-1086-622-1654-0.html
OJS UK Science Publication. (2023). Efficacy of montelukast and fexofenadine combination in allergic rhinitis: A systematic review. ENT Update, 5(2), 1–9. https://ojs.ukscip.com/index.php/ENTU/article/view/874
PharmEasy. (2024). Montelukast + Fexofenadine: Uses, side effects, and precautions. Retrieved October 21, 2025, from https://pharmeasy.in/molecules/montelukast-fexofenadine-7840
Sanofi India Ltd. (2024). Allegra-M prescribing information (Montelukast 10 mg + Fexofenadine 120 mg) [PDF]. Retrieved October 21, 2025, from https://www.sanofi.com/assets/countries/india/docs/consumer-healthcare/for-healthcare-professionals/products-information/allegra-m-pi-6-2-25.pdf
Search BVS (Biblioteca Virtual en Salud). (2022). Post-marketing observational study of montelukast + fexofenadine combination in Indian patients with allergic rhinitis. Retrieved October 21, 2025, from https://search.bvsalud.org/gim/resource/en/sea-157539
Steris Online. (2023). Comprehensive guide to Montelukast 10 mg + Fexofenadine 120 mg (Monteluke-F). Retrieved October 21, 2025, from https://www.sterisonline.com/blog/montelukast-10mg-fexofenadine-120mg-comprehensive-guide-to-monteluke-f
TrueMeds. (2024). Drug salts: Fexofenadine + Montelukast. Retrieved October 21, 2025, from https://www.truemeds.in/drug-salts/fexofenadine-montelukast-139
Wikipedia. (2025, October 12). Fexofenadine. In Wikipedia. Retrieved October 21, 2025, from https://en.wikipedia.org/wiki/Fexofenadine
Wikipedia. (2025, October 10). Montelukast. In Wikipedia. Retrieved October 21, 2025, from https://en.wikipedia.org/wiki/Montelukast